The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease

Neurology

Volumn 63, Issue 2, 2004, Pages 214-219

  Holmes, Clive ^a   Wilkinson, D ^a   Dean, C ^a   Vethanayagam, S ^b   Olivieri, S ^c   Langley, A ^d   Pandita Gunawardena, N D ^e   Hogg, F ^f   Clare, C ^a   Damms, J ^f  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b Dept of Mental Hlth for Elderly ^*  (United Kingdom)

^c Melbury Lodge   (United Kingdom)

^d Pepperville House   (United Kingdom)

^e UNIVERSITY HOSPITAL LEWISHAM   (United Kingdom)

^f ST MARY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE; CHOLINESTERASE INHIBITOR; DONEPEZIL; NEUROLEPTIC AGENT; PLACEBO; PSYCHOTROPIC AGENT;

ADULT; ALZHEIMER DISEASE; ARTICLE; CAREGIVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NEUROLOGIC DISEASE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SYMPTOMATOLOGY; TREATMENT OUTCOME;

EID: 3242775357     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000129990.32253.7B     Document Type: Article

References (19)

1. Rovner BW, Kafonek S, Fillipp T, et al. Prevalence of mental illness in a community nursing home. Am J Psychiatry 1986;143:1446-1449.
2. Tariot PN, Podgorski CA, Blazina L, et al. Mental disorders in the nursing home: another perspective. Am J Psychiatry 1993;39:440-449.
3. Minger SL, Esiri MM, McDonald B, et al. Cholinergic deficits Contribute to behavioural disturbance in patients with dementia. Neurology 2000;55:1460-1467.
4. Cummings JL. Cholinesterase inhibitors: a new class of psychotropic compounds. Am J Psychiatry 2000;157:4-15.
5. Trinh NH, Hoblyn J, Mohanty S, Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer's disease: a meta-analysis. JAMA 2003;289:210-216.
6. Gauthier S, Feldman H, Hecker J, et al. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. Int Psychogeriatr 2003;14:389-404.
7. Winblad B, Brodaty H, Gauthier S, et al. Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success? Int J Geriatr Psychiatry 2001;16:653-666.
8. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
9. Cummings JL, Mega M, Gray K, Rosenburg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-2314.
10. Folstein MF, Folstein SE, McHugh PR. Mini Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
11. Feldman H, Gauthier S, Hecker J, et al. A 24 week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001;57:613-620.
12. Cummings JL, Donohue JA, Brooks RL, et al. The relationship between donepezil and behavioral disturbances in patients with Alzheimer's disease. Am J Geriatr Psychiatry 2000;8:134-140.
13. Wiener MF, Martin-Cook K, Foster BM, et al. Effects of donepezil on emotional/behavioral symptoms in Alzheimer's disease patients. J Clin Psychiatry 2000;61:487-492.
14. Tariot PN, Cummings JL, Katz IR, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. JAGS 2001;49:1590-1599.
15. De Deyn PP, Rabheru K, Rasmussen A, et al. A randomized trial of risperidone, placebo and haloperidol for behavioral symptoms of dementia. Neurology 1999;53:946-955.
16. Lovestone S, Graham N, Howard R. Guidelines on drug treatments for Alzheimer's disease. Lancet 1997;350:232-233.
17. Doody RS, Geldmacher DS, Gordon B, Perdomo CA, Pratt RD, Donepezil Study Group. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol 2001;58:427-433.
18. Holmes C, Fortenza O, Powell J, Lovestone S. Do neuroleptics hasten cognitive decline: carriers of APOE ε4 seem particularly susceptible to their effects. BMJ 1997;314:1411.
19. McShane R, Keene J, Fairburn C, Jacoby R, Hope T. Issues in drug treatment for Alzheimer's disease. Lancet 1997;350:886-887.